Skip to main content
Oxford University Hospitals NHS Foundation Trust

Coronavirus / COVID-19

If you have a new continuous cough, a high temperature, or a loss or change to your sense of taste or smell, do not come to our hospitals. Follow the national advice.

Please find information on our services and visiting restrictions in our COVID-19 section.

Patients and visitors must wear a face covering in our hospitals.

This site is best viewed with a modern browser. You appear to be using an old version of Internet Explorer.

Blood loss medication does not reduce death from stomach bleeding, trial finds


A study involving researchers from Oxford University Hospitals NHS Foundation Trust has recommended that tranexamic acid, routinely used to treat excessive blood loss, should not be used for the treatment of gastrointestinal bleeding.

The results of the HALT-IT trial, a six-year international collaboration, were published in the Lancet on 20 June.

The trial found that tranexamic acid, often used to counteract excessive bleeding during surgery or after major trauma or childbirth, did not reduce deaths from gastrointestinal bleeding but actually increased the risk of deep vein thrombosis or pulmonary embolism. There were also more seizures in those given tranexamic acid. 

“It is often assumed that a treatment that works in one bleeding situation will probably work in another, but this trial has shown otherwise. Our results highlight the need for clinical trials that target specific causes of bleeding,” said Prof Simon Stanworth, Consultant Haematologist at the John Radcliffe Hospital for NHS Blood & Transplant and OUH, who was a member of the trial team.

“On the basis of these results, we recommend that tranexamic acid should not be used to treat gastrointestinal bleeding, although it has an important role in other patients with major bleeding, such as trauma and post-partum haemorrhage.”

More than 12,000 patients with acute gastrointestinal bleeding took part in this randomised, double-blind trial, half receiving a high-dose 24-hour infusion of tranexamic acid, and the rest a placebo. The trial was conducted 164 hospitals in 15 countries. 

The number of patients who died due to bleeding within five days of randomisation was the same, 4%, in both groups, as was the rate of heart attack and stroke (0.7% versus 0.8%).

The level of deep vein thrombosis or pulmonary embolism in the tranexamic acid group was double that in the placebo group (0·8% against 0·4%).

In the UK, the trial was funded by the NIHR’s Health Technology Assessment Programme.